Regeneron (REGN) files Form 144 to resell 400 shares via J.P. Morgan
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Regeneron Pharmaceuticals filed a Form 144 notice for the proposed sale of 400 shares of Common Stock through J.P. Morgan Securities LLC at its New York address. The filing also records a prior sale of 100 shares on 05/01/2026 for $70,523.79.
Positive
- None.
Negative
- None.
Insights
Routine affiliate resale notice for a small quantity of shares.
The filing is a Form 144 disclosure that lists 400 shares of Common Stock to be sold through J.P. Morgan Securities LLC. It also documents a prior sale of 100 shares on 05/01/2026 for $70,523.79.
Regulatory treatment is procedural: Form 144 notifies the market of an affiliate's intent to sell under exemptions. Timing, methods of sale, and net proceeds are not specified in the excerpt.
Key Figures
Shares proposed for resale: 400 shares
Prior sale: 100 shares
Value of prior sale: $70,523.79
3 metrics
Shares proposed for resale
400 shares
Form 144 listing via J.P. Morgan Securities LLC
Prior sale
100 shares
Sold on 05/01/2026
Value of prior sale
$70,523.79
Proceeds reported for 100-share sale on 05/01/2026
Key Terms
Form 144, Compensation, Securities Sold During The Past 3 Months
3 terms
Form 144 regulatory
"144: Securities To Be Sold Common Stock"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Compensation financial
"Common Stock | 08/22/2013 | Compensation | Issuer"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months Arthur F. Ryan"
FAQ
What does the REGN Form 144 disclose?
It discloses a proposed resale of 400 shares of Regeneron common stock via J.P. Morgan and records a prior sale of 100 shares on 05/01/2026 for $70,523.79. This is a regulatory notice by an affiliate.
Who is the broker handling the proposed sale in the REGN filing?
J.P. Morgan Securities LLC at 270 Park Avenue, New York, is listed as the broker for the 400-share resale. The filing provides the broker's address and identifies the broker as the intermediary for the proposed transaction.
Does the Form 144 state how proceeds will be used?
The excerpt does not state use of proceeds. The filing lists the number of shares and broker but does not disclose proceeds allocation, timing, or specific sale mechanics in the provided text.